The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners.